Use of Thalidomide for Severe Recurrent Aphthous Stomatitis
- 1 May 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 89 (3), 176-182
- https://doi.org/10.1097/md.0b013e3181dfca14
Abstract
Severe recurrent aphthous stomatitis (SRAS) is a rare, disabling disorder of unknown etiology. Thalidomide is an effective second-line therapy for SRAS, but is suppressive rather than curative, and adverse events limit its use. Few reports describe the efficacy, tolerance, and safety of thalidomide, and how it is actually used as long-term (maintenance) therapy for SRAS. Therefore, we conducted this study to describe thalidomide use in the real-life management of a cohort of patients with SRAS. This multicenter retrospective cohort study covered a period of 5 years and 5 months (January 2003-May 2008). Patients who had started thalidomide monotherapy for SRAS during the 2003-2006 period were eligible. Data were collected from patients' medical charts and supplemented by patients' responses during a targeted telephone interview. Ninety-two patients followed at 14 centers were included: 76 had oral or bipolar aphthosis, and 16 had Behçet disease. Thalidomide was rapidly effective: 85% (78/92) entered complete remission (CR) within a median of 14 days. Response time was independent of the initial thalidomide dose (r = 0.04). Thalidomide was continued for > or =3 months (maintenance therapy) by 77/92 (84%) of the patients on 1 of 2 maintenance regimens: continuous therapy with regular intake (60/77) or intermittent therapy in response to attacks (17/77). Although intermittent therapy was less restrictive than continuous therapy, medical supervision under the former was less rigorous. The median maintenance dose was 100 mg/week, and did not reflect the initial dose (r = 0.18). The intermittent-treatment group's median dose was significantly lower and its median duration of thalidomide intake significantly longer than for patients on continuous therapy (19 vs. 150 mg/wk; p < 0.0001, and 32 vs. 19 mo; p = 0.002, respectively). Adverse events were reported by 84% (77/92) of patients. They were mostly mild (78% of patients), but sometimes severe (21%). Nevertheless, after 40 months of follow-up, 60% of patients were still receiving continuous or intermittent maintenance therapy with favorable efficacy/tolerance ratios. Despite its retrospective nature, this detailed study provides novel information on the different ways thalidomide is used as SRAS maintenance therapy in a large and unselected cohort of patients. Low-dose maintenance regimens appear to be widely used, effective, and relatively well tolerated. These observations suggest the value of undertaking a randomized trial to assess various maintenance regimens.Keywords
This publication has 14 references indexed in Scilit:
- Risk indicators for recurrent aphthous ulcers among adults in the USCommunity Dentistry and Oral Epidemiology, 2007
- Complex aphthosis: A large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomideJournal of the American Academy of Dermatology, 2005
- Assessment of oral health related quality of lifeHealth and Quality of Life Outcomes, 2003
- Incidence and Risk Factors for Thalidomide Neuropathy: a Prospective Study of 135 Dermatologic PatientsJournal of Investigative Dermatology, 2002
- Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet SyndromeAnnals of Internal Medicine, 1998
- Recurrent aphthous stomatitis: Clinical characteristics and associated systemic disordersSeminars in Cutaneous Medicine and Surgery, 1997
- Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy.Annals Of The Rheumatic Diseases, 1994
- Thalidomide Neuropathy Incidence and Clinicoelectrophysiologic Findings in 42 PatientsArchives of Dermatology, 1994
- Significant response of oral aphthosis to thalidomide treatmentJournal of the American Academy of Dermatology, 1985
- THALIDOMIDE IN SEVERE OROGENITAL ULCERATIONThe Lancet, 1984